Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Cristian Lolli 1 , Umberto Basso 2 , Lisa Derosa 3 , Emanuela Scarpi 1 , Teodoro Sava 4 , Matteo Santoni 5 , Simon J. Crabb 6 , Francesco Massari 4, 8 , Michele Aieta 7 , Vincenza Conteduca 1 , Marco Maruzzo 2 , Francesca La Russa 4 , Matthew Wheater 6 , Rossana Berardi 5 , Luca Galli 3 , Ugo De Giorgi 1 1 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2 Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy 3 Oncology Unit 2, University Hospital of Pisa, Pisa, Italy 4 Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy 5 Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy 6 Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, UK 7 Department of Medical Oncology, IRCCS CROB Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy 8 Present address: Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy Correspondence to: Ugo De Giorgi, email: ugo.degiorgi@irst.emr.it Keywords: systemic immune inflammation index, renal cell carcinoma, RCC, prognostic factor, sunitinib Received: April 20, 2016 Accepted: May 23, 2016 Published: July 09, 2016 ABSTRACT Background: In this retrospective analysis, we explored the prognostic and predictive value of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and platelet counts, at baseline and changes at week 6 during first-line sunitinib in patients with metastatic renal cell cancer (RCC). Results: Patients were stratified into high SII (≥ 730) and low SII (< 730) groups. SII was associated with objective response, p < 0.0001. The median PFS was 6.3 months (95% CI 5.5–8.9) in patients with SII ≥ 730 and 18.7 months (95% CI 14.7–22.8) in those with SII < 730, p < 0.0001. The median OS was 43.6 months (95% CI 35.3–52.1) in patients with SII < 730, and 13.5 months (95% CI 9.8–18.5) in those with SII ≥ 730, p < 0.0001. In multivariate analysis, performance status, IMDC score and SII were able to predict OS (HR = 3.29, HR = 1.71 and HR = 1.79, respectively). Materials and Methods: We included 335 consecutive RCC patients treated with first-line sunitinib. The X-tile 3.6.1 software (Yale University, New Haven, CT) was used for bioinformatic analysis of the data to determine the cutoff value of SII. Progression-free survival (PFS), overall survival (OS) and their 95% confidence interval (95% CI) were estimated by Kaplan-Meier method and compared with logrank test. The impact of SII conversion at week 6 of treatment on PFS and OS was evaluated by Cox regression analyses. Conclusions: The SII and its changes during treatment represent a powerful prognostic indicator of clinical outcome in patients with metastatic RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“In addition, this inflammatory index is of special interest in RCC, which is an immune-responsive disease, and new immune-oncologic agents, like checkpoint inhibitors are in active development as agents for the treatment of systemic disease [28].”
BackgroundHu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Labelle, M., Begum, S., & Hynes, R. O. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.009 · Cited by 1,833
Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395
Cited by
Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis
Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W. (2018) · Journal of Cancer · doi:10.7150/jca.25691 · Cited by 441
Zhong, J.-H., Huang, D.-H., & Chen, Z.-Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18856 · Cited by 307
Systemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
“Similar data were reported by the same group and others in kidney cancer, oesophageal squamous, hepatocellular, gastric or colorectal carcinoma (Huang et al, 2016; Passardi et al, 2016; Wang et al, 2016; Lolli et al, 2016a; Feng et al, 2017).”
MethodResultFankhauser, C. D., Sander, S., Roth, L., Gross, O., Eberli, D., Sulser, T., Seifert, B., Beyer, J., & Hermanns, T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.467 · Cited by 80
Cursano, M. C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gallà, V., Santini, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01325 · Cited by 19
Self-citation
Metadata
- Authors
- Lolli, C., Basso, U., Derosa, L., Scarpi, E., Sava, T., Santoni, M., Crabb, S. J., Massari, F., Aieta, M., Conteduca, V., Maruzzo, M., La Russa, F., Wheater, M., Berardi, R., Galli, L., & De Giorgi, U.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-07-09
- Volume
- 7
- Issue
- 34
- Pages
- 54564-54571
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2464839949
- Cited by
- 155
- References
- 5
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.